The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OPN-6602, an investigational therapy for relapsed/refractory multiple myeloma, according to regulatory filings and industry sources. The status aims to expedite development of drugs addressing unmet medical needs.
OPN-6602, developed by OncoPharma Neuroscience, targets a novel pathway in plasma cell malignancies. Analysts note this marks the third Fast Track designation for myeloma therapies in 2026, reflecting heightened focus on the blood cancer affecting over 35,000 Americans annually.
‘Fast Track enables more frequent FDA interactions and potential priority review,’ said a biotech analyst familiar with the application, speaking on condition of anonymity due to client relationships. The designation doesn’t guarantee approval but allows rolling submission of clinical data.
Phase 2 trial data presented at December’s ASH conference showed a 42% overall response rate in heavily pretreated patients, though with grade 3+ adverse events occurring in 28% of participants. The FDA’s decision appears based on these interim results while awaiting final Phase 3 data expected Q4 2027.
Market observers suggest this could pressure established CAR-T therapies if OPN-6602 demonstrates comparable efficacy with simpler administration. However, some clinicians caution that confirmatory trials must validate early promising results before changing treatment paradigms.